Blueprint Medicines

Deciphera Pharmaceuticals

This biopharmaceutical company develops and commercialises kinase-inhibiting drugs for patients with cancer, immunological diseases, and neurological conditions.

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Kinnate Biopharma

The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Syndax

This biopharmaceutical company develops and commercialises targeted therapies for adult and paediatric patients with cancer and chronic graft-versus-host disease.

iDRx

This biopharmaceutical company develops precision combination therapies targeting genetic drivers and resistance mutations for patients with gastrointestinal stromal tumours.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.